Genmab A/S

The current price of GMAB is $55.12 — it has decreased by 0.72% since the previous close. Data as of Nov 4, 2026.

GMAB is down 3.97% over the past week, up 58.62% over the past month and up 91.66% over the past year. The price is above its 200-day moving average of $30.73.

Analysts' average 12-month price target for GMAB is $50.60, which implies 8.20% downside from the current price. Individual estimates range from $40.00 to $70.00.

Of the 12 analysts covering Genmab A/S, 1 rates it a strong buy, 10 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Genmab A/S has a market capitalization of $33.89B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Genmab A/S posted earnings of $0.54 per share against an estimate of $0.37, beating expectations by 45.95%. Upcoming reports are listed in the earnings calendar.

Genmab A/S reported revenue of $1.16B in its most recent quarter, which has increased by 24.89% compared with the same quarter a year earlier. Analysts had expected $1.12B.

Genmab A/S has not paid any dividends over the past year.

Companies most comparable to Genmab A/S include Incyte Corporation, BioNTech SE, Exelixis, Inc., Iovance Biotherapeutics, Inc. and Legend Biotech Corporation.

In the latest trading session GMAB moved between $53.76 and $56.20, a range of 4.43% of its current price.

Over the past 52 weeks GMAB has traded between $23.62 and $59.97. The current price is 8.09% below its 52-week high.